Siemens shuffles U.S. execs
Other headlinesGE study supports imaging use
Siemens shuffles U.S. execs
The U.S. operations of Siemens Healthcare will have a new leader. Effective July 1, Michael Reitermann will serve as CEO of the U.S. organization, in charge of marketing, sales, and service of medical imaging, therapy and health care information technology. He will be based at U.S. headquarters in Malvern, PA. Reitermann succeeds Heinrich Kolem, Ph.D., who served as CEO since 2006. Kolem will now run global operations for Siemens Healthcare’s angiography, fluoroscopy and X-ray business unit, based in Forchheim, Germany. Reitermann was CEO of Siemens Molecular Imaging Business Unit since July 2002 and president of the former nuclear medicine division. Previously he worked as a senior project manager at Siemens corporate strategies division, as well as a partner in Siemens Management Consulting. He served as vice president for sales, marketing and innovation of the Siemens angiography, fluoroscopy and X-ray business unit.
GE study supports imaging use
A GE Healthcare study documents that medical lowers patient mortality at hospitals, yet has little or no effect on length of stay or cost. The study, led by David Lee, Ph.D., senior director of GE Health Economics and Outcomes Research, was presented this week at the 2009 Academy Health Annual Research Meeting in Chicago. Based on the experience of more one million patients across more than 100 U.S. hospitals, the study contradicts common assumptions that diagnostic imaging services, including those of CT, MR, ultrasound and x-ray, add to admission-related costs.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
